These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 10319882

  • 1. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.
    Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, Sakamoto M.
    Ann Neurol; 1999 May; 45(5):601-10. PubMed ID: 10319882
    [Abstract] [Full Text] [Related]

  • 2. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M.
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [Abstract] [Full Text] [Related]

  • 3. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, Hanson RN, Madras BK.
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [Abstract] [Full Text] [Related]

  • 6. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [Abstract] [Full Text] [Related]

  • 7. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
    Yagi S, Yoshikawa E, Futatsubashi M, Yokokura M, Yoshihara Y, Torizuka T, Ouchi Y.
    J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
    [Abstract] [Full Text] [Related]

  • 8. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ, Im JH, Yang SO, Moon DH, Ryu JS, Bong JK, Nam KP, Cheon JH, Lee MC, Lee HK.
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [Abstract] [Full Text] [Related]

  • 9. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
    Berding G, Brücke T, Odin P, Brooks DJ, Kolbe H, Gielow P, Harke H, Knoop BO, Dengler R, Knapp WH.
    Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W.
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ.
    Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
    [Abstract] [Full Text] [Related]

  • 16. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
    Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO.
    Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
    [Abstract] [Full Text] [Related]

  • 17. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
    Kim SE, Lee WY, Choe YS, Kim JH.
    Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
    [Abstract] [Full Text] [Related]

  • 18. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB.
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.